Moderate inhibition of acetylcholinesterase (AChE; 0.65 ± 0.08 mg GALAE/particles) and more pronounced inhibition of butyrylcholinesterase (BChE; 3.50 ± 0.05 mg GALAE/particles) suggest a potential role in supporting neurotransmitter function, particularly in the later stages of Alzheimer’s disease where BChE becomes predominant [68]. This evidence concerns the gene ACHE and Alzheimer disease.